Penserra Capital Management LLC purchased a new position in Johnson & Johnson (NYSE:JNJ) in the third quarter, HoldingsChannel reports. The firm purchased 3,200 shares of the company’s stock, valued at approximately $416,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. BlackRock Inc. lifted its holdings in shares of Johnson & Johnson by 2.6% in the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after buying an additional 4,332,612 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Johnson & Johnson by 717.9% in the second quarter. Janus Henderson Group PLC now owns 3,748,008 shares of the company’s stock worth $495,837,000 after buying an additional 3,289,763 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Johnson & Johnson by 1.5% in the second quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after buying an additional 3,023,110 shares in the last quarter. Parametric Portfolio Associates LLC lifted its holdings in shares of Johnson & Johnson by 47.9% in the second quarter. Parametric Portfolio Associates LLC now owns 7,970,670 shares of the company’s stock worth $1,054,433,000 after buying an additional 2,581,562 shares in the last quarter. Finally, Harbour Capital Advisors LLC lifted its holdings in shares of Johnson & Johnson by 13,327.8% in the second quarter. Harbour Capital Advisors LLC now owns 2,501,472 shares of the company’s stock worth $18,909,000 after buying an additional 2,482,843 shares in the last quarter. Institutional investors and hedge funds own 65.70% of the company’s stock.

Several equities analysts have recently commented on JNJ shares. Goldman Sachs Group downgraded shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and boosted their target price for the stock from $125.00 to $130.00 in a report on Wednesday, September 20th. Vetr raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 target price on the stock in a report on Monday, October 30th. Credit Suisse Group set a $154.00 target price on shares of Johnson & Johnson and gave the stock an “outperform” rating in a report on Thursday, October 19th. BMO Capital Markets boosted their target price on shares of Johnson & Johnson to $161.00 and gave the stock an “outperform” rating in a report on Tuesday, December 12th. Finally, Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. Four analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $145.52.

Shares of Johnson & Johnson (NYSE JNJ) opened at $143.97 on Thursday. The stock has a market cap of $386,780.00, a price-to-earnings ratio of 24.99, a P/E/G ratio of 2.67 and a beta of 0.80. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. Johnson & Johnson has a 12 month low of $110.76 and a 12 month high of $145.68.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The company had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. During the same quarter in the prior year, the firm earned $1.68 earnings per share. Johnson & Johnson’s revenue was up 10.3% on a year-over-year basis. equities analysts forecast that Johnson & Johnson will post 7.28 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.33%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s dividend payout ratio is currently 58.33%.

TRADEMARK VIOLATION WARNING: “Penserra Capital Management LLC Takes Position in Johnson & Johnson (JNJ)” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/penserra-capital-management-llc-takes-position-in-johnson-johnson-jnj/1802535.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.